HRP20231236T1 - Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora - Google Patents
Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora Download PDFInfo
- Publication number
- HRP20231236T1 HRP20231236T1 HRP20231236TT HRP20231236T HRP20231236T1 HR P20231236 T1 HRP20231236 T1 HR P20231236T1 HR P20231236T T HRP20231236T T HR P20231236TT HR P20231236 T HRP20231236 T HR P20231236T HR P20231236 T1 HRP20231236 T1 HR P20231236T1
- Authority
- HR
- Croatia
- Prior art keywords
- membered
- group
- optionally substituted
- groups
- salt
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title claims 2
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title claims 2
- 230000001713 cholinergic effect Effects 0.000 title claims 2
- 229940126027 positive allosteric modulator Drugs 0.000 title claims 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 206010010774 Constipation Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- OSODMBOLSCKSAX-RXVVDRJESA-N 7-[[3-fluoro-4-(2-methoxyethylcarbamoyl)phenyl]methyl]-N-[(3R,4S)-3-hydroxyoxan-4-yl]-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide Chemical compound FC=1C=C(CC2=C3C(=NC(=C2)C(=O)N[C@@H]2[C@H](COCC2)O)CCO3)C=CC=1C(NCCOC)=O OSODMBOLSCKSAX-RXVVDRJESA-N 0.000 claims 1
- DTXNQISTOJXZPJ-NYDSKATKSA-N 7-[[3-fluoro-4-[[(2S)-oxolan-2-yl]methylcarbamoyl]phenyl]methyl]-N-[(3R,4S)-3-hydroxyoxan-4-yl]-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide Chemical compound FC=1C=C(CC2=C3C(=NC(=C2)C(=O)N[C@@H]2[C@H](COCC2)O)CCO3)C=CC=1C(NC[C@H]1OCCC1)=O DTXNQISTOJXZPJ-NYDSKATKSA-N 0.000 claims 1
- CCWOFYZOWGTZQY-NYDSKATKSA-N 7-[[3-fluoro-4-[[(2S)-oxolan-2-yl]methylcarbamoyl]phenyl]methyl]-N-[(3R,4S)-3-hydroxyoxan-4-yl]furo[3,2-b]pyridine-5-carboxamide Chemical compound FC=1C=C(CC2=C3C(=NC(=C2)C(=O)N[C@@H]2[C@H](COCC2)O)C=CO3)C=CC=1C(NC[C@H]1OCCC1)=O CCWOFYZOWGTZQY-NYDSKATKSA-N 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- JAOKSPSCQSULJJ-UWJYYQICSA-N N-[(3R,4S)-3-hydroxyoxan-4-yl]-7-[[4-(1-methyltriazol-4-yl)phenyl]methyl]-2,3-dihydrofuro[3,2-b]pyridine-5-carboxamide Chemical compound O[C@H]1COCC[C@@H]1NC(=O)C1=CC(=C2C(=N1)CCO2)CC1=CC=C(C=C1)C=1N=NN(C=1)C JAOKSPSCQSULJJ-UWJYYQICSA-N 0.000 claims 1
- KDAYHBHQHWHAOK-UWJYYQICSA-N N-[(3R,4S)-3-hydroxyoxan-4-yl]-7-[[4-(1-methyltriazol-4-yl)phenyl]methyl]furo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@H]1COCC[C@@H]1NC(=O)C1=CC(=C2C(=N1)C=CO2)CC1=CC=C(C=C1)C=1N=NN(C=1)C KDAYHBHQHWHAOK-UWJYYQICSA-N 0.000 claims 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001555 benzenes Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj, naznačen time, da je predstavljen formulom (I):
[image]
u kojoj
R1 je opcionalno supstituirana ciklička skupina;
R2 je atom vodika, atom halogena, cijano skupina, opcionalno supstituirana C1-6 alkilna skupina, ili opcionalno supstituirana C1-6 alkoksi skupina;
[image]
je jednostruka veza ili dvostruka veza;
prsten A je opcionalno nadalje supstituirani prsten; i
R3 i R4 su svaki neovisno atom vodika, atom halogena, hidroksi skupina, opcionalno supstituirana C1-6 alkilna skupina ili opcionalno supstituirana C1-6 alkoksi skupina,
ili njegova sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da
R1 je
(1) opcionalno supstituirana 3-člana do 14-člana nearomatska heterociklička skupina, ili
(2) opcionalno supstituirana C3-10 cikloalkilna skupina;
R2 je atom vodika ili opcionalno supstituirana C1-6 alkilna skupina;
prsten A je
(1) opcionalno nadalje supstituirani benzenski prsten,
(2) opcionalno nadalje supstituirani 5-člani ili 6-člani monociklički aromatski heterocikl,
(3) opcionalno nadalje supstituirani 4-člani do 6-člani monociklički nearomatski heterocikl, ili
(4) opcionalno nadalje supstituirani 9-člani do 14-člani kondenzirani policiklički nearomatski heterocikl; i
R3 i R4 su svaki neovisno atom vodika, atom halogena ili opcionalno supstituirana C1-6 alkilna skupina,
ili njegova sol.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da
R1 je
(1) 3-člana do 14-člana nearomatska heterociklička skupina opcionalno supstituirana s 1 do 3 hidroksi skupine, ili
(2) C3-10 cikloalkilna skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana između hidroksi skupine i atoma halogena;
R2 je atom vodika ili C1-6 alkilna skupina;
prsten A je
(1) benzenski prsten opcionalno nadalje supstituiran s 1 do 3 supstituenta odabrana između (a) atoma halogena, (b) C1-6 alkoksi skupine, (c) mono- ili di-C1-6 alkil-karbamoilne skupine opcionalno supstituirane s 1 ili 2 supstituenta odabrana između (i) C1-6 alkoksi skupine, (ii) C3-10 cikloalkilne skupine, (iii) 3-člane do 14-člane nearomatske heterocikličke skupine, (iv) C6-14 arilne skupine opcionalno supstituirane s 1 do 3 hidroksi skupine, (v) C1-6 alkoksikarbonilne skupine, (vi) karboksi skupine, (vii) C1-6 alkiltio skupine, (viii) mono- ili di-C1-6 alkil-karbamoilne skupine, i (ix) 3-člane do 14-člane nearomatske heterociklilkarbonilne skupine, (d) mono- ili di-C3-10 cikloalkil-karbamoilne skupine, (e) C6-14 aril-karbamoilne skupine opcionalno supstituirane s 1 do 3 hidroksi skupine, i (f) 5-člane do 14-člane aromatske heterocikličke skupine opcionalno supstituirane s 1 do 3 C1-6 alkil skupine,
(2) 5-člani ili 6-člani monociklički aromatski heterocikl opcionalno nadalje supstituiran s 1 do 3 supstituenta odabrana između (a) C1-6 alkoksi skupine i (b) 5-člane do 14-člane aromatske heterocikličke skupine opcionalno supstituirane s 1 do 3 C1-6 alkilne skupine,
(3) 4-člani do 6-člani monociklički nearomatski heterocikl opcionalno nadalje supstituiran s jednom okso skupinom, ili
(4) 9-člani do 14-člani kondenzirani policiklički nearomatski heterocikl opcionalno nadalje supstituiran s 1 do 3 supstituenta odabrana između C1-6 alkilne skupine i okso skupine; i
R3 i R4 su svaki neovisno atom vodika, atom halogena ili C1-6 alkilna skupina,
ili njegova sol.
4. Spoj prema patentnom zahtjevu 3, naznačen time, da
R1 je
[image]
[image]
ili njegova sol.
5. Spoj prema patentnom zahtjevu 3, naznačen time, da
prsten A je
(1) benzenski prsten nadalje supstituiran s 1 do 3 supstituenta odabrana između (a) atoma halogena, (b) mono- ili di-C1-6 alkil-karbamoilne skupine opcionalno supstituirane s 1 ili 2 supstituenta odabrana između (i) C1-6 alkoksi skupine i (ii) 3-člane do 14-člane nearomatske heterocikličke skupine, i (c) 5-člane do 14-člane aromatske heterocikličke skupine opcionalno supstituirane s 1 do 3 C1-6 alkilne skupine, ili
(2) 5-člani ili 6-člani monociklički aromatski heterocikl dodatno supstituiran s jednom 5-članom do 14-članom aromatskom heterocikličkom skupinom opcionalno supstituiranom s 1 do 3 C1-6 alkilne skupine,
ili njegova sol.
6. Spoj prema patentnom zahtjevu 3, naznačen time, da
prsten A je
[image]
gdje R5A je mono- ili di-C1-6 alkil-karbamoilna skupina opcionalno supstituirana s 1 ili 2 supstituenta odabrana između C1-6 alkoksi skupine i 3-člane do 14-člane nearomatske heterocikličke skupine;
X je CR6A ili N; i
R6A je atom vodika ili atom halogena,
ili njegova sol.
7. Spoj prema patentnom zahtjevu 1, naznačen time, da
R1 je 3-člana do 14-člana nearomatska heterociklička skupina supstituirana s jednom hidroksi skupinom;
R2 je atom vodika;
prsten A je
(1) benzenski prsten nadalje supstituiran s 1 do 3 supstituenta odabrana između (a) atoma halogena, (b) mono- ili di-C1-6 alkil-karbamoilne skupine opcionalno supstituirane s 1 ili 2 supstituenta odabrana između (i) C1-6 alkoksi skupine i (ii) 3-člane do 14-člane nearomatske heterocikličke skupine, i (c) 5-člane do 14-člane aromatske heterocikličke skupine opcionalno supstituirane s 1 do 3 C1-6 alkilne skupine, ili
(2) 5-člani ili 6-člani monociklički aromatski heterocikl koji je nadalje supstituiran jednom 5-članom do 14-članom aromatskom heterocikličkom skupinom opcionalno supstituiranom s 1 do 3 C1-6 alkilne grupe; i
R3 i R4 su svaki neovisno atom vodika ili atom halogena,
ili njegova sol.
8. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj N-((3R,4S)-3-hidroksitetrahidro-2H-piran-4-il)-7-(4-(1-metil-1H-1,2,3-triazol-4-il)benzil)furo[3,2-b]piridin-5-karboksamid, ili njegova sol.
9. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj N-((3R,4S)-3-hidroksitetrahidro-2H-piran-4-il)-7-(4-(1-metil-1H-1,2,3-triazol-4-il)benzil)-2,3-dihidrofuro[3,2-b]piridin-5-karboksamid, ili njegova sol.
10. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj 7-(3-fluoro-4-((2-metoksietil)karbamoil)benzil)-N-((3R,4S)-3-hidroksitetrahidro-2H-piran-4-il)-2,3-dihidrofuro[3,2-b]piridin-5-karboksamid, ili njegova sol.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj 7-(3-fluoro-4-((((S)-tetrahidrofuran-2-il)metil)karbamoil)benzil)-N-((3R,4S)-3-hidroksitetrahidro-2H-piran-4-il)-2,3-dihidrofuro[3,2-b]piridin-5-karboksamid, ili njegova sol.
12. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj 7-(3-fluoro-4-((((S)-tetrahidrofuran-2-il)metil)karbamoil)benzil)-N-((3R,4S)-3-hidroksitetrahidro-2H-piran-4-il)furo[3,2-b]piridin-5-karboksamid, ili njegova sol.
13. Lijek, naznačen time, da sadrži spoj prema patentnom zahtjevu 1 ili njegovu sol.
14. Lijek prema patentnom zahtjevu 13, naznačen time, da je pozitivni alosterički modulator kolinergičkog muskarinskog M1 receptora.
15. Lijek prema patentnom zahtjevu 13, naznačen time, da je profilaktičko ili terapeutsko sredstvo za konstipaciju.
16. Spoj prema patentnom zahtjevu 1 ili njegova sol, naznačen time, da je za uporabu u profilaksi ili liječenju konstipacije.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017120859 | 2017-06-20 | ||
| JP2018005960 | 2018-01-17 | ||
| US201862683418P | 2018-06-11 | 2018-06-11 | |
| PCT/JP2018/023357 WO2018235838A1 (ja) | 2017-06-20 | 2018-06-19 | 複素環化合物 |
| EP18819596.0A EP3643718B1 (en) | 2017-06-20 | 2018-06-19 | Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231236T1 true HRP20231236T1 (hr) | 2024-02-16 |
Family
ID=64737123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231236TT HRP20231236T1 (hr) | 2017-06-20 | 2018-06-19 | Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11236099B2 (hr) |
| DK (1) | DK3643718T3 (hr) |
| ES (1) | ES2960408T3 (hr) |
| FI (1) | FI3643718T3 (hr) |
| HR (1) | HRP20231236T1 (hr) |
| HU (1) | HUE063823T2 (hr) |
| LT (1) | LT3643718T (hr) |
| MX (1) | MX2021015514A (hr) |
| PL (1) | PL3643718T3 (hr) |
| PT (1) | PT3643718T (hr) |
| RS (1) | RS64722B1 (hr) |
| SI (1) | SI3643718T1 (hr) |
| WO (1) | WO2018235838A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078164C (en) * | 2017-10-27 | 2022-11-15 | Suven Life Sciences Limited | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
| WO2020067457A1 (ja) * | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| JP4710445B2 (ja) * | 2004-07-08 | 2011-06-29 | 田辺三菱製薬株式会社 | 医薬組成物 |
| DK2512243T3 (en) | 2009-12-17 | 2016-07-25 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC QUINOLINAMIDE M1 RECEPTOR MODULATORS |
| EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| EP2709621B1 (en) | 2011-05-17 | 2016-11-02 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| NZ725921A (en) | 2014-04-23 | 2023-09-29 | Takeda Pharmaceuticals Co | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2015190564A1 (ja) | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2017120859A (ja) | 2015-12-28 | 2017-07-06 | 帝人株式会社 | 組紐状圧電素子、組紐状圧電素子を用いた布帛状圧電素子およびそれらを用いたデバイス |
| CA3014791A1 (en) * | 2016-02-16 | 2017-08-24 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2017155050A1 (ja) | 2016-03-11 | 2017-09-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| JP2018005960A (ja) | 2016-07-01 | 2018-01-11 | エヌイーシー ショット コンポーネンツ株式会社 | 接触子を有する気密端子 |
| KR102017786B1 (ko) | 2016-09-02 | 2019-09-03 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 포지티브 알로스테릭 조절제 |
| US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
-
2018
- 2018-06-19 US US16/622,632 patent/US11236099B2/en active Active
- 2018-06-19 ES ES18819596T patent/ES2960408T3/es active Active
- 2018-06-19 HU HUE18819596A patent/HUE063823T2/hu unknown
- 2018-06-19 PT PT188195960T patent/PT3643718T/pt unknown
- 2018-06-19 SI SI201831003T patent/SI3643718T1/sl unknown
- 2018-06-19 FI FIEP18819596.0T patent/FI3643718T3/fi active
- 2018-06-19 DK DK18819596.0T patent/DK3643718T3/da active
- 2018-06-19 PL PL18819596.0T patent/PL3643718T3/pl unknown
- 2018-06-19 WO PCT/JP2018/023357 patent/WO2018235838A1/ja active Application Filing
- 2018-06-19 HR HRP20231236TT patent/HRP20231236T1/hr unknown
- 2018-06-19 RS RS20230955A patent/RS64722B1/sr unknown
- 2018-06-19 LT LTEPPCT/JP2018/023357T patent/LT3643718T/lt unknown
-
2019
- 2019-12-19 MX MX2021015514A patent/MX2021015514A/es unknown
-
2021
- 2021-09-15 US US17/475,733 patent/US20220017530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021015514A (es) | 2022-02-22 |
| US11236099B2 (en) | 2022-02-01 |
| FI3643718T3 (fi) | 2023-11-01 |
| DK3643718T3 (da) | 2023-11-06 |
| LT3643718T (lt) | 2023-10-25 |
| SI3643718T1 (sl) | 2023-11-30 |
| US20220017530A1 (en) | 2022-01-20 |
| HUE063823T2 (hu) | 2024-02-28 |
| US20210139491A1 (en) | 2021-05-13 |
| PT3643718T (pt) | 2023-10-26 |
| RS64722B1 (sr) | 2023-11-30 |
| ES2960408T3 (es) | 2024-03-04 |
| WO2018235838A1 (ja) | 2018-12-27 |
| PL3643718T3 (pl) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| EA201492112A1 (ru) | ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА | |
| CY1124284T1 (el) | Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53 | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201791239A1 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| CO2017011038A2 (es) | Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca” | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201490287A1 (ru) | Новые замещенные производные индола в качестве модуляторов гамма-секретазы | |
| HRP20231236T1 (hr) | Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora | |
| EA201790122A1 (ru) | Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| EA201290655A1 (ru) | Новые производные замещенного бициклического триазола в качестве модуляторов гамма-секретазы | |
| UY38979A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CL2011001378A1 (es) | Compuestos derivados de pirimidin oxi-indoles, inhibidores de vegf-r2; composicion farmaceutica que los comprende; uso en el tratamiento de una enfermedad o trastorno proliferativo tales como enfermedades tumorales y enfermedades de neovascularizacion ocular. | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| PE20151788A1 (es) | Inhibidores de bromodominios tetraciclicos | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| EA201171363A1 (ru) | Новые замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы | |
| NZ702539A (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| EA201992679A1 (ru) | N-замещенные индольные производные | |
| EA201691930A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1 | |
| AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
| PE20220386A1 (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK |